Recombinantly produced allergens

US9757447B2 · kind B2 · utility

Assignee

• PHADIA AB · SE

Inventors

• Lars Mattsson · Uppsala, SE
• Jonas Lidholm · Knivsta, SE
• Thomas Lundgren · Uppsala, SE

Key dates

• Filing date: Dec 30, 2015
• Grant date: Sep 12, 2017
• Expiry date: Dec 30, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/24
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods for producing an allergen composition, methods for in vitro diagnosis of type I allergy, and diagnostic kits for performing diagnosis employ Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein. Methods for treatment of a Type I allergy to a mammal and pharmaceutical compositions employ a Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein, wherein the Bos d 23k allergen, the mature protein, the variant or the fragment is modified to abrogate or attenuate its IgE binding response.